The implementation of NSCLC testing recommendations in the clinical setting can be challenging, particularly as NSCLC guideline recommendations have expanded to testing for molecular biomarkers other than EGFR/ALK genomic alterations, including ROS1 and BRAF, in addition to PD-L1 [26,27]. This evidence concerns the gene ALK and non-small cell lung carcinoma.